Therefore canagliflozin, which regimen had higher SGLT1 inhibitory effects than the other SGLT2 inhibitors [177], would have a possibility of intestine obstruction beyond a class-level effect. This evidence concerns the gene SLC5A1 and intestinal obstruction.